Price to Book Value (P/BV)
since 2005
Calculation
Bristol-Myers Squibb Co., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Total BMS shareholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | 6.98 | = | 56.15 | ÷ | 8.05 | 8.05 | = | 16,335 | ÷ | 2,029,312,023 | |
| Feb 13, 2024 | 3.35 | = | 48.71 | ÷ | 14.55 | 14.55 | = | 29,430 | ÷ | 2,022,193,411 | |
| Feb 14, 2023 | 4.88 | = | 72.25 | ÷ | 14.80 | 14.80 | = | 31,061 | ÷ | 2,098,775,978 | |
| Feb 9, 2022 | 4.07 | = | 67.14 | ÷ | 16.49 | 16.49 | = | 35,946 | ÷ | 2,179,712,820 | |
| Feb 10, 2021 | 3.55 | = | 60.00 | ÷ | 16.88 | 16.88 | = | 37,822 | ÷ | 2,240,475,153 | |
| Feb 24, 2020 | 2.80 | = | 63.97 | ÷ | 22.86 | 22.86 | = | 51,598 | ÷ | 2,257,510,796 | |
| Feb 25, 2019 | 5.89 | = | 50.65 | ÷ | 8.59 | 8.59 | = | 14,031 | ÷ | 1,632,675,877 | |
| Feb 13, 2018 | 8.88 | = | 63.87 | ÷ | 7.19 | 7.19 | = | 11,741 | ÷ | 1,632,582,502 | |
| Feb 21, 2017 | 5.66 | = | 54.78 | ÷ | 9.67 | 9.67 | = | 16,177 | ÷ | 1,672,715,340 | |
| Feb 12, 2016 | 7.04 | = | 60.20 | ÷ | 8.55 | 8.55 | = | 14,266 | ÷ | 1,669,459,090 | |
| Feb 13, 2015 | 6.72 | = | 60.04 | ÷ | 8.94 | 8.94 | = | 14,852 | ÷ | 1,662,118,446 | |
| Feb 14, 2014 | 5.92 | = | 54.37 | ÷ | 9.18 | 9.18 | = | 15,154 | ÷ | 1,650,232,566 | |
| Feb 15, 2013 | 4.40 | = | 36.58 | ÷ | 8.32 | 8.32 | = | 13,623 | ÷ | 1,637,354,662 | |
| Feb 17, 2012 | 3.50 | = | 33.12 | ÷ | 9.45 | 9.45 | = | 15,956 | ÷ | 1,688,107,071 | |
| Feb 18, 2011 | 2.76 | = | 25.49 | ÷ | 9.23 | 9.23 | = | 15,713 | ÷ | 1,702,427,438 | |
| Feb 19, 2010 | 2.88 | = | 24.95 | ÷ | 8.66 | 8.66 | = | 14,843 | ÷ | 1,714,140,539 | |
| Feb 20, 2009 | 3.29 | = | 20.37 | ÷ | 6.18 | 6.18 | = | 12,241 | ÷ | 1,979,509,306 | |
| Feb 22, 2008 | 4.22 | = | 22.53 | ÷ | 5.34 | 5.34 | = | 10,562 | ÷ | 1,979,387,706 | |
| Feb 26, 2007 | 5.50 | = | 27.19 | ÷ | 4.95 | 4.95 | = | 9,991 | ÷ | 2,019,481,440 | |
| Mar 14, 2006 | 4.00 | = | 22.91 | ÷ | 5.72 | 5.72 | = | 11,208 | ÷ | 1,959,073,035 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Bristol-Myers Squibb Co. Annual Report.
The data reveals the evolution of the share price, book value per share (BVPS), and price-to-book value (P/BV) ratio over a span of 20 years. The share price generally demonstrates an upward trend with fluctuations, starting at $22.91 in 2006, rising significantly to peaks above $60 in several years such as 2014, 2015, 2018, and 2021, before declining again in later years. Notably, the share price reached a low point of $20.37 in 2009, suggesting potential market or company-specific challenges during that period. Following this low, the price increased steadily until 2015 and showed volatility thereafter, with occasional declines.
The book value per share (BVPS) indicates varying trends, initially rising from $5.72 in 2006 to a peak of $9.67 in 2017. However, from 2018 onward, the BVPS fluctuates considerably, with a significant jump in 2020 to $22.86, followed by sharp declines to $8.05 by 2025. This pattern signals potential changes in the company’s asset base, equity structure, or financial adjustments that impact the book value. The substantial rise in 2020 might reflect an extraordinary event or accounting adjustment, while subsequent declines suggest reversals or other financial impacts.
The price-to-book value (P/BV) ratio fluctuates widely, ranging from a low of 2.8 in 2020 to a high of 8.88 in 2018. Generally, the P/BV ratio trends higher in the mid-2010s, peaking in 2016–2018, coinciding with moderate BVPS values but elevated share prices. The lower P/BV ratio in 2020 corresponds with the notable surge in BVPS that year, reducing the ratio despite relatively stable share prices. The volatility in this metric over time highlights changes in market valuation relative to book value, which may be influenced by investor sentiment, growth expectations, or financial restructurings.
Overall, the financial data reflects periods of volatility in both market valuation and book value, with significant shifts occurring around the years 2009, 2017–2020, and into the mid-2020s. The interrelationship among share price, BVPS, and P/BV suggests that the company experienced varying phases of growth, market perception, and financial restructuring over the analyzed timeframe.
Comparison to Competitors
Bristol-Myers Squibb Co., P/BV, long-term trends, comparison to competitors
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2025 | 6.98 | 102.40 | 26.61 | 3.00 | 57.93 | 7.36 | 5.30 | 4.99 | 1.68 | 2.67 | 4.09 | 7.24 |
| Feb 13, 2024 | 3.35 | 29.97 | 24.94 | 3.47 | 65.80 | 4.01 | 5.48 | 8.68 | 1.75 | 3.96 | 4.57 | 6.26 |
| Feb 14, 2023 | 4.88 | 15.52 | 35.01 | 3.64 | 29.36 | 4.90 | 5.37 | 6.07 | 2.48 | 3.77 | 4.83 | 5.50 |
| Feb 9, 2022 | 4.07 | 16.53 | 18.51 | 4.16 | 25.28 | 3.65 | 5.90 | 5.05 | 3.35 | 3.60 | 5.18 | 6.16 |
| Feb 10, 2021 | 3.55 | 14.18 | 14.53 | 3.93 | 35.07 | 4.33 | 6.72 | 7.46 | 2.98 | 4.81 | 5.15 | 6.30 |
| Feb 24, 2020 | 2.80 | — | 13.84 | 3.72 | 51.67 | 3.93 | 6.61 | 7.83 | 3.00 | 3.79 | 4.16 | 10.23 |
| Feb 25, 2019 | 5.89 | — | 9.41 | 2.80 | 12.87 | 3.89 | 6.08 | 7.79 | 3.80 | 5.07 | 3.75 | 10.68 |
| Feb 13, 2018 | 8.88 | 36.95 | 5.02 | 2.58 | 7.33 | 5.15 | 5.79 | 4.30 | 2.94 | 5.66 | 3.30 | 20.14 |
| Feb 21, 2017 | 5.66 | 21.24 | 4.14 | 2.56 | 6.33 | 4.88 | 4.72 | 4.51 | 3.40 | 8.58 | 2.86 | 18.42 |
| Feb 12, 2016 | 7.04 | 22.17 | 3.94 | 2.53 | 5.51 | 6.59 | 4.07 | 3.15 | 2.84 | 10.53 | 2.42 | 22.38 |
| Feb 13, 2015 | 6.72 | 56.09 | 4.59 | 2.63 | 5.14 | 10.08 | 4.01 | 3.42 | 2.95 | 16.22 | 2.51 | 25.60 |
| Feb 14, 2014 | 5.92 | 18.05 | 4.30 | 2.38 | 3.69 | 11.36 | 3.50 | 3.35 | 2.69 | 16.74 | 2.90 | 14.77 |
| Feb 15, 2013 | 4.40 | 18.06 | 3.57 | 2.23 | 4.15 | 7.01 | 3.29 | 2.44 | 2.42 | 12.91 | 1.72 | 10.08 |
| Feb 17, 2012 | 3.50 | — | 2.83 | 2.17 | 3.35 | 5.08 | 3.13 | 2.14 | 1.95 | 19.19 | 1.38 | 10.05 |
| Feb 18, 2011 | 2.76 | — | 2.04 | 2.39 | 3.21 | 5.29 | 2.88 | 1.85 | 1.75 | 6.42 | 1.41 | 16.16 |
| Feb 19, 2010 | 2.88 | — | 2.46 | 2.07 | 4.17 | 6.74 | 3.45 | 1.97 | 1.57 | 5.49 | 1.29 | 7.45 |
| Feb 20, 2009 | 3.29 | — | 2.48 | 1.69 | 5.01 | 9.83 | 3.56 | 2.72 | 1.44 | 2.94 | 1.02 | 21.09 |
| Feb 22, 2008 | 4.22 | — | 2.77 | 2.62 | 4.16 | 11.76 | 4.17 | 5.38 | 2.32 | 3.24 | 1.62 | 8.92 |
| Feb 26, 2007 | 5.50 | — | 3.96 | 3.32 | 5.43 | 18.07 | 4.78 | 5.45 | 2.49 | 5.77 | 1.38 | 7.52 |
| Mar 14, 2006 | 4.00 | — | 4.26 | 3.78 | 5.85 | 9.18 | 4.66 | 4.30 | 2.94 | 8.16 | 2.03 | 18.12 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Bristol-Myers Squibb Co., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Bristol-Myers Squibb Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 12, 2025 | 6.98 | 7.03 |
| Feb 13, 2024 | 3.35 | 6.77 |
| Feb 14, 2023 | 4.88 | 5.66 |
| Feb 9, 2022 | 4.07 | 5.72 |
| Feb 10, 2021 | 3.55 | 5.99 |
| Feb 24, 2020 | 2.80 | 5.82 |
| Feb 25, 2019 | 5.89 | 6.02 |
| Feb 13, 2018 | 8.88 | 5.14 |
| Feb 21, 2017 | 5.66 | 4.58 |
| Feb 12, 2016 | 7.04 | 4.15 |
| Feb 13, 2015 | 6.72 | 4.47 |
| Feb 14, 2014 | 5.92 | 3.97 |
| Feb 15, 2013 | 4.40 | 3.21 |
| Feb 17, 2012 | 3.50 | 2.55 |
| Feb 18, 2011 | 2.76 | 2.25 |
| Feb 19, 2010 | 2.88 | 2.37 |
| Feb 20, 2009 | 3.29 | 2.60 |
| Feb 22, 2008 | 4.22 | 3.42 |
| Feb 26, 2007 | 5.50 | 3.82 |
| Mar 14, 2006 | 4.00 | 4.00 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Bristol-Myers Squibb Co., P/BV, long-term trends, comparison to industry (health care)
| Bristol-Myers Squibb Co. | Health Care | |
|---|---|---|
| Feb 12, 2025 | 6.98 | 5.48 |
| Feb 13, 2024 | 3.35 | 5.44 |
| Feb 14, 2023 | 4.88 | 78,500.89 |
| Feb 9, 2022 | 4.07 | 5.07 |
| Feb 10, 2021 | 3.55 | 4.90 |
| Feb 24, 2020 | 2.80 | 4.71 |
| Feb 25, 2019 | 5.89 | 4.72 |
| Feb 13, 2018 | 8.88 | 4.35 |
| Feb 21, 2017 | 5.66 | 3.91 |
| Feb 12, 2016 | 7.04 | 3.54 |
| Feb 13, 2015 | 6.72 | 4.01 |
| Feb 14, 2014 | 5.92 | 3.40 |
| Feb 15, 2013 | 4.40 | 2.77 |
| Feb 17, 2012 | 3.50 | 2.42 |
| Feb 18, 2011 | 2.76 | 2.15 |
| Feb 19, 2010 | 2.88 | 2.26 |
| Feb 20, 2009 | 3.29 | 2.47 |
| Feb 22, 2008 | 4.22 | 3.28 |
| Feb 26, 2007 | 5.50 | 3.77 |
| Mar 14, 2006 | 4.00 | 3.94 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).